RossT.The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature1993;362:801–9.
2.
LibbyP.Molecular bases of the acute coronary syndromes. Circulation1995;91:2844–50.
3.
RidkerPM, CushmanM, StampferMJ, TraceyRP, HennekensCH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med1997;336:973–9.
4.
RidkerPM, CushmanM, StampferMJ, TracyRP, HennekensCH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation1998;97:425–8.
5.
RidkerPM, GlynnRJ, HennekensCH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation1998;97:2007–11.
6.
RidkerPM, BuringJE, ShihJ, MatiasM, HennekensCH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation1998;98:731–3.
7.
KullerLH, TracyRP, ShatenJ, MeilahnEN, for the. MRFIT Research Group. Relationship of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol1996;144:537–47.
8.
TracyRP, LemaitreRN, PsatyBM, IvesDG, EvansRW, CushmanM, MeilahnEN, KullerLH. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol1997;17:1121–7.
9.
LiuzzoG, BiasucciLM, GallimoreJR, GrilloRL, RebuzziAG, PepysMB, MaseriA.The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med1994;331:417–24.
10.
ThompsonSG, KienastJ, PykeSDM, HaverkateF, van de LooJCW, for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med1995;332:635–41.
11.
HaverkateF, ThompsonSG, PykeSDM, GallimoreJR, PepysMB, for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet1997;349:462–66.
12.
RidkerPM, RifaiN, PfefferMA, SacksFM, MoyeLA, GoldmanS, FlakerGC, BraunwaldE for the Cholesterol and Recurrent Events (CARE) Investigators. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation1998;98:839–44.
13.
MacyEM, HayesTE, TracyRP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference interval and epidemiological applications. Clin Chem1997;43:52–8.
14.
WilkinsJ, GallimoreR, MooreEG, PepysMB. Rapid automated high sensitivity enzyme immunoassay of C-reactive protein. Clin Chem1998;44:1358–61.
15.
BerkBC, WeintraubWS, AlexanderRW. Elevation of C-reactive protein in “active” coronary disease. Am J Cardiol1990;65:168–72.
16.
KoenigW, FroehlichM, SundM, DoeringA, FischerHG, LowelH, HutchinsonW, PepyesMB. C-Reactive protein predicts risk of coronary heart disease in middle-aged men: results from the MONICA Augsberg Cohort Study, [abstract]. Circulation1997;96:199.
17.
TracyRP. Inflammation in cardiovascular disease. Cart, horse, or both?Circulation1998;97:2000–2.
18.
van der WalAC, BeckerAE, van der LoosCM, DasPK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation1994;89:36–44.
19.
CermakJ, KeyNS, BachRR, C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood1993;82:513–20.
20.
ReynoldsGD, VanceRP. C-reactive protein immunohistochemical localization in normal and atherosclerotic human aortas. Arch Pathol Lab Med1987;111:265–9.
21.
BuchtaR, PontetM, FiedelM.Binding of C-reactive protein to human neutrophils. FEBS Lett1987;211:165–8.
22.
WolbinkGJ, BrouwerMC, BuysmannS, ten BergeIJM, HackCE. C-reactive protein mediated activation of complement in vivo. Assessment by measuring circulating complement-C-reactive protein complexes. J Immunol1996;157:473–9.
23.
ZoukiC, BeauchampM, BaronC, FilepJG. Prevention of in vitro neutrophil adhesion to endothelial cells through shedding of L-selectin by C-reactive protein and peptides derived from C-reactive protein. J Clin Invest1997;100:522–9.
24.
RidkerPM, HennekensCH, Roitman-JohnsonB, StampferMJ, AllenJ.Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet1998;351:88–92.
25.
BatailleR, KelinB.C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. Arthritis Rheum1992;35:982–4.
26.
RidkerPM. Inflammation, infection, and cardiovascular disease: how good is the clinical evidence?Circulation1998;98:1671–4.
